Lymphangioleiomyomatosis (LAM)

DBCOND0042291Hemic and Lymphatic DiseasesImmune System Diseases

Lymphangioleiomyomatosis (LAM) is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as
Lymphangioleiomyomatosis · Lymphangiomyomatosis
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0027421ICD-10J84.81SNOMED CT73017001MedDRA10049459UMLSC0751674

What you can answer from here — as of November 02, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
30Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Drug reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Lymphangioleiomyomatosis (LAM) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In